Summary

The global Neuroendocrine Tumor Drug market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The impact of the latest U.S. tariff measures and the corresponding policy responses from countries worldwide on market competitiveness, regional economic performance, and supply chain configurations will be comprehensively evaluated in this report.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LP Information, Inc. (LPI) ' newest research report, the “Neuroendocrine Tumor Drug Industry Forecast” looks at past sales and reviews total world Neuroendocrine Tumor Drug sales in 2024, providing a comprehensive analysis by region and market sector of projected Neuroendocrine Tumor Drug sales for 2025 through 2031. With Neuroendocrine Tumor Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Neuroendocrine Tumor Drug industry.
This Insight Report provides a comprehensive analysis of the global Neuroendocrine Tumor Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Neuroendocrine Tumor Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Neuroendocrine Tumor Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Neuroendocrine Tumor Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Neuroendocrine Tumor Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Neuroendocrine Tumor Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by Type:
mTOR Protein Inhibitors
Tyrosine Kinase 3 Inhibitors
Somatostatin Receptor Antagonists
Growth Hormone Releasing Factor Antagonists
Somatostatin Receptor Agonists
Others
Segmentation by Application:
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Eisai
Exelixis, Inc.
Foresee Pharmaceuticals, LLC
Hutchison MediPharma Limited
Intezyne, Inc
INVENT Pharmaceuticals, Inc.
Ipsen S.A.
Jiangsu Hengrui Medicine Co., Ltd.
Karyopharm Therapeutics, Inc.
Lexicon Pharmaceuticals, Inc.
Midatech Pharma Plc .
Millennium Pharmaceuticals, Inc.
MolMed S.p.A.
Northwest Biotherapeutics, Inc.
Novartis AG
OctreoPharm Sciences GmbH
OXiGENE, Inc.
Key Questions Addressed in this Report
What is the 10-year outlook for the global Neuroendocrine Tumor Drug market?
What factors are driving Neuroendocrine Tumor Drug market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Neuroendocrine Tumor Drug market opportunities vary by end market size?
How does Neuroendocrine Tumor Drug break out by Type, by Application?

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuroendocrine Tumor Drug Annual Sales 2020-2031
2.1.2 World Current & Future Analysis for Neuroendocrine Tumor Drug by Geographic Region, 2020, 2024 & 2031
2.1.3 World Current & Future Analysis for Neuroendocrine Tumor Drug by Country/Region, 2020, 2024 & 2031
2.2 Neuroendocrine Tumor Drug Segment by Type
2.2.1 mTOR Protein Inhibitors
2.2.2 Tyrosine Kinase 3 Inhibitors
2.2.3 Somatostatin Receptor Antagonists
2.2.4 Growth Hormone Releasing Factor Antagonists
2.2.5 Somatostatin Receptor Agonists
2.2.6 Others
2.3 Neuroendocrine Tumor Drug Sales by Type
2.3.1 Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
2.3.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Type (2020-2025)
2.3.3 Global Neuroendocrine Tumor Drug Sale Price by Type (2020-2025)
2.4 Neuroendocrine Tumor Drug Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Neuroendocrine Tumor Drug Sales by Application
2.5.1 Global Neuroendocrine Tumor Drug Sale Market Share by Application (2020-2025)
2.5.2 Global Neuroendocrine Tumor Drug Revenue and Market Share by Application (2020-2025)
2.5.3 Global Neuroendocrine Tumor Drug Sale Price by Application (2020-2025)
3 Global by Company
3.1 Global Neuroendocrine Tumor Drug Breakdown Data by Company
3.1.1 Global Neuroendocrine Tumor Drug Annual Sales by Company (2020-2025)
3.1.2 Global Neuroendocrine Tumor Drug Sales Market Share by Company (2020-2025)
3.2 Global Neuroendocrine Tumor Drug Annual Revenue by Company (2020-2025)
3.2.1 Global Neuroendocrine Tumor Drug Revenue by Company (2020-2025)
3.2.2 Global Neuroendocrine Tumor Drug Revenue Market Share by Company (2020-2025)
3.3 Global Neuroendocrine Tumor Drug Sale Price by Company
3.4 Key Manufacturers Neuroendocrine Tumor Drug Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Neuroendocrine Tumor Drug Product Location Distribution
3.4.2 Players Neuroendocrine Tumor Drug Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.6 New Products and Potential Entrants
3.7 Market M&A Activity & Strategy
4 World Historic Review for Neuroendocrine Tumor Drug by Geographic Region
4.1 World Historic Neuroendocrine Tumor Drug Market Size by Geographic Region (2020-2025)
4.1.1 Global Neuroendocrine Tumor Drug Annual Sales by Geographic Region (2020-2025)
4.1.2 Global Neuroendocrine Tumor Drug Annual Revenue by Geographic Region (2020-2025)
4.2 World Historic Neuroendocrine Tumor Drug Market Size by Country/Region (2020-2025)
4.2.1 Global Neuroendocrine Tumor Drug Annual Sales by Country/Region (2020-2025)
4.2.2 Global Neuroendocrine Tumor Drug Annual Revenue by Country/Region (2020-2025)
4.3 Americas Neuroendocrine Tumor Drug Sales Growth
4.4 APAC Neuroendocrine Tumor Drug Sales Growth
4.5 Europe Neuroendocrine Tumor Drug Sales Growth
4.6 Middle East & Africa Neuroendocrine Tumor Drug Sales Growth
5 Americas
5.1 Americas Neuroendocrine Tumor Drug Sales by Country
5.1.1 Americas Neuroendocrine Tumor Drug Sales by Country (2020-2025)
5.1.2 Americas Neuroendocrine Tumor Drug Revenue by Country (2020-2025)
5.2 Americas Neuroendocrine Tumor Drug Sales by Type (2020-2025)
5.3 Americas Neuroendocrine Tumor Drug Sales by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroendocrine Tumor Drug Sales by Region
6.1.1 APAC Neuroendocrine Tumor Drug Sales by Region (2020-2025)
6.1.2 APAC Neuroendocrine Tumor Drug Revenue by Region (2020-2025)
6.2 APAC Neuroendocrine Tumor Drug Sales by Type (2020-2025)
6.3 APAC Neuroendocrine Tumor Drug Sales by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Neuroendocrine Tumor Drug by Country
7.1.1 Europe Neuroendocrine Tumor Drug Sales by Country (2020-2025)
7.1.2 Europe Neuroendocrine Tumor Drug Revenue by Country (2020-2025)
7.2 Europe Neuroendocrine Tumor Drug Sales by Type (2020-2025)
7.3 Europe Neuroendocrine Tumor Drug Sales by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neuroendocrine Tumor Drug by Country
8.1.1 Middle East & Africa Neuroendocrine Tumor Drug Sales by Country (2020-2025)
8.1.2 Middle East & Africa Neuroendocrine Tumor Drug Revenue by Country (2020-2025)
8.2 Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2020-2025)
8.3 Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Neuroendocrine Tumor Drug
10.3 Manufacturing Process Analysis of Neuroendocrine Tumor Drug
10.4 Industry Chain Structure of Neuroendocrine Tumor Drug
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Neuroendocrine Tumor Drug Distributors
11.3 Neuroendocrine Tumor Drug Customer
12 World Forecast Review for Neuroendocrine Tumor Drug by Geographic Region
12.1 Global Neuroendocrine Tumor Drug Market Size Forecast by Region
12.1.1 Global Neuroendocrine Tumor Drug Forecast by Region (2026-2031)
12.1.2 Global Neuroendocrine Tumor Drug Annual Revenue Forecast by Region (2026-2031)
12.2 Americas Forecast by Country (2026-2031)
12.3 APAC Forecast by Region (2026-2031)
12.4 Europe Forecast by Country (2026-2031)
12.5 Middle East & Africa Forecast by Country (2026-2031)
12.6 Global Neuroendocrine Tumor Drug Forecast by Type (2026-2031)
12.7 Global Neuroendocrine Tumor Drug Forecast by Application (2026-2031)
13 Key Players Analysis
13.1 Eisai
13.1.1 Eisai Company Information
13.1.2 Eisai Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.1.3 Eisai Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.1.4 Eisai Main Business Overview
13.1.5 Eisai Latest Developments
13.2 Exelixis, Inc.
13.2.1 Exelixis, Inc. Company Information
13.2.2 Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.2.3 Exelixis, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.2.4 Exelixis, Inc. Main Business Overview
13.2.5 Exelixis, Inc. Latest Developments
13.3 Foresee Pharmaceuticals, LLC
13.3.1 Foresee Pharmaceuticals, LLC Company Information
13.3.2 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.3.3 Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.3.4 Foresee Pharmaceuticals, LLC Main Business Overview
13.3.5 Foresee Pharmaceuticals, LLC Latest Developments
13.4 Hutchison MediPharma Limited
13.4.1 Hutchison MediPharma Limited Company Information
13.4.2 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.4.3 Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.4.4 Hutchison MediPharma Limited Main Business Overview
13.4.5 Hutchison MediPharma Limited Latest Developments
13.5 Intezyne, Inc
13.5.1 Intezyne, Inc Company Information
13.5.2 Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.5.3 Intezyne, Inc Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.5.4 Intezyne, Inc Main Business Overview
13.5.5 Intezyne, Inc Latest Developments
13.6 INVENT Pharmaceuticals, Inc.
13.6.1 INVENT Pharmaceuticals, Inc. Company Information
13.6.2 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.6.3 INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.6.4 INVENT Pharmaceuticals, Inc. Main Business Overview
13.6.5 INVENT Pharmaceuticals, Inc. Latest Developments
13.7 Ipsen S.A.
13.7.1 Ipsen S.A. Company Information
13.7.2 Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.7.3 Ipsen S.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.7.4 Ipsen S.A. Main Business Overview
13.7.5 Ipsen S.A. Latest Developments
13.8 Jiangsu Hengrui Medicine Co., Ltd.
13.8.1 Jiangsu Hengrui Medicine Co., Ltd. Company Information
13.8.2 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.8.3 Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.8.4 Jiangsu Hengrui Medicine Co., Ltd. Main Business Overview
13.8.5 Jiangsu Hengrui Medicine Co., Ltd. Latest Developments
13.9 Karyopharm Therapeutics, Inc.
13.9.1 Karyopharm Therapeutics, Inc. Company Information
13.9.2 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.9.3 Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.9.4 Karyopharm Therapeutics, Inc. Main Business Overview
13.9.5 Karyopharm Therapeutics, Inc. Latest Developments
13.10 Lexicon Pharmaceuticals, Inc.
13.10.1 Lexicon Pharmaceuticals, Inc. Company Information
13.10.2 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.10.3 Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.10.4 Lexicon Pharmaceuticals, Inc. Main Business Overview
13.10.5 Lexicon Pharmaceuticals, Inc. Latest Developments
13.11 Midatech Pharma Plc .
13.11.1 Midatech Pharma Plc . Company Information
13.11.2 Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.11.3 Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.11.4 Midatech Pharma Plc . Main Business Overview
13.11.5 Midatech Pharma Plc . Latest Developments
13.12 Millennium Pharmaceuticals, Inc.
13.12.1 Millennium Pharmaceuticals, Inc. Company Information
13.12.2 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.12.3 Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.12.4 Millennium Pharmaceuticals, Inc. Main Business Overview
13.12.5 Millennium Pharmaceuticals, Inc. Latest Developments
13.13 MolMed S.p.A.
13.13.1 MolMed S.p.A. Company Information
13.13.2 MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.13.3 MolMed S.p.A. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.13.4 MolMed S.p.A. Main Business Overview
13.13.5 MolMed S.p.A. Latest Developments
13.14 Northwest Biotherapeutics, Inc.
13.14.1 Northwest Biotherapeutics, Inc. Company Information
13.14.2 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.14.3 Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.14.4 Northwest Biotherapeutics, Inc. Main Business Overview
13.14.5 Northwest Biotherapeutics, Inc. Latest Developments
13.15 Novartis AG
13.15.1 Novartis AG Company Information
13.15.2 Novartis AG Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.15.3 Novartis AG Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.15.4 Novartis AG Main Business Overview
13.15.5 Novartis AG Latest Developments
13.16 OctreoPharm Sciences GmbH
13.16.1 OctreoPharm Sciences GmbH Company Information
13.16.2 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.16.3 OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.16.4 OctreoPharm Sciences GmbH Main Business Overview
13.16.5 OctreoPharm Sciences GmbH Latest Developments
13.17 OXiGENE, Inc.
13.17.1 OXiGENE, Inc. Company Information
13.17.2 OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
13.17.3 OXiGENE, Inc. Neuroendocrine Tumor Drug Sales, Revenue, Price and Gross Margin (2020-2025)
13.17.4 OXiGENE, Inc. Main Business Overview
13.17.5 OXiGENE, Inc. Latest Developments
14 Research Findings and Conclusion

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Neuroendocrine Tumor Drug Annual Sales CAGR by Geographic Region (2020, 2024 & 2031) & ($ millions)
Table 2. Neuroendocrine Tumor Drug Annual Sales CAGR by Country/Region (2020, 2024 & 2031) & ($ millions)
Table 3. Major Players of mTOR Protein Inhibitors
Table 4. Major Players of Tyrosine Kinase 3 Inhibitors
Table 5. Major Players of Somatostatin Receptor Antagonists
Table 6. Major Players of Growth Hormone Releasing Factor Antagonists
Table 7. Major Players of Somatostatin Receptor Agonists
Table 8. Major Players of Others
Table 9. Global Neuroendocrine Tumor Drug Sales by Type (2020-2025) & (K Pcs)
Table 10. Global Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Table 11. Global Neuroendocrine Tumor Drug Revenue by Type (2020-2025) & ($ million)
Table 12. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2020-2025)
Table 13. Global Neuroendocrine Tumor Drug Sale Price by Type (2020-2025) & (USD/Pcs)
Table 14. Global Neuroendocrine Tumor Drug Sale by Application (2020-2025) & (K Pcs)
Table 15. Global Neuroendocrine Tumor Drug Sale Market Share by Application (2020-2025)
Table 16. Global Neuroendocrine Tumor Drug Revenue by Application (2020-2025) & ($ million)
Table 17. Global Neuroendocrine Tumor Drug Revenue Market Share by Application (2020-2025)
Table 18. Global Neuroendocrine Tumor Drug Sale Price by Application (2020-2025) & (USD/Pcs)
Table 19. Global Neuroendocrine Tumor Drug Sales by Company (2020-2025) & (K Pcs)
Table 20. Global Neuroendocrine Tumor Drug Sales Market Share by Company (2020-2025)
Table 21. Global Neuroendocrine Tumor Drug Revenue by Company (2020-2025) & ($ millions)
Table 22. Global Neuroendocrine Tumor Drug Revenue Market Share by Company (2020-2025)
Table 23. Global Neuroendocrine Tumor Drug Sale Price by Company (2020-2025) & (USD/Pcs)
Table 24. Key Manufacturers Neuroendocrine Tumor Drug Producing Area Distribution and Sales Area
Table 25. Players Neuroendocrine Tumor Drug Products Offered
Table 26. Neuroendocrine Tumor Drug Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
Table 27. New Products and Potential Entrants
Table 28. Market M&A Activity & Strategy
Table 29. Global Neuroendocrine Tumor Drug Sales by Geographic Region (2020-2025) & (K Pcs)
Table 30. Global Neuroendocrine Tumor Drug Sales Market Share Geographic Region (2020-2025)
Table 31. Global Neuroendocrine Tumor Drug Revenue by Geographic Region (2020-2025) & ($ millions)
Table 32. Global Neuroendocrine Tumor Drug Revenue Market Share by Geographic Region (2020-2025)
Table 33. Global Neuroendocrine Tumor Drug Sales by Country/Region (2020-2025) & (K Pcs)
Table 34. Global Neuroendocrine Tumor Drug Sales Market Share by Country/Region (2020-2025)
Table 35. Global Neuroendocrine Tumor Drug Revenue by Country/Region (2020-2025) & ($ millions)
Table 36. Global Neuroendocrine Tumor Drug Revenue Market Share by Country/Region (2020-2025)
Table 37. Americas Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K Pcs)
Table 38. Americas Neuroendocrine Tumor Drug Sales Market Share by Country (2020-2025)
Table 39. Americas Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & ($ millions)
Table 40. Americas Neuroendocrine Tumor Drug Sales by Type (2020-2025) & (K Pcs)
Table 41. Americas Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (K Pcs)
Table 42. APAC Neuroendocrine Tumor Drug Sales by Region (2020-2025) & (K Pcs)
Table 43. APAC Neuroendocrine Tumor Drug Sales Market Share by Region (2020-2025)
Table 44. APAC Neuroendocrine Tumor Drug Revenue by Region (2020-2025) & ($ millions)
Table 45. APAC Neuroendocrine Tumor Drug Sales by Type (2020-2025) & (K Pcs)
Table 46. APAC Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (K Pcs)
Table 47. Europe Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K Pcs)
Table 48. Europe Neuroendocrine Tumor Drug Revenue by Country (2020-2025) & ($ millions)
Table 49. Europe Neuroendocrine Tumor Drug Sales by Type (2020-2025) & (K Pcs)
Table 50. Europe Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (K Pcs)
Table 51. Middle East & Africa Neuroendocrine Tumor Drug Sales by Country (2020-2025) & (K Pcs)
Table 52. Middle East & Africa Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2025)
Table 53. Middle East & Africa Neuroendocrine Tumor Drug Sales by Type (2020-2025) & (K Pcs)
Table 54. Middle East & Africa Neuroendocrine Tumor Drug Sales by Application (2020-2025) & (K Pcs)
Table 55. Key Market Drivers & Growth Opportunities of Neuroendocrine Tumor Drug
Table 56. Key Market Challenges & Risks of Neuroendocrine Tumor Drug
Table 57. Key Industry Trends of Neuroendocrine Tumor Drug
Table 58. Neuroendocrine Tumor Drug Raw Material
Table 59. Key Suppliers of Raw Materials
Table 60. Neuroendocrine Tumor Drug Distributors List
Table 61. Neuroendocrine Tumor Drug Customer List
Table 62. Global Neuroendocrine Tumor Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 63. Global Neuroendocrine Tumor Drug Revenue Forecast by Region (2026-2031) & ($ millions)
Table 64. Americas Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 65. Americas Neuroendocrine Tumor Drug Annual Revenue Forecast by Country (2026-2031) & ($ millions)
Table 66. APAC Neuroendocrine Tumor Drug Sales Forecast by Region (2026-2031) & (K Pcs)
Table 67. APAC Neuroendocrine Tumor Drug Annual Revenue Forecast by Region (2026-2031) & ($ millions)
Table 68. Europe Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 69. Europe Neuroendocrine Tumor Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 70. Middle East & Africa Neuroendocrine Tumor Drug Sales Forecast by Country (2026-2031) & (K Pcs)
Table 71. Middle East & Africa Neuroendocrine Tumor Drug Revenue Forecast by Country (2026-2031) & ($ millions)
Table 72. Global Neuroendocrine Tumor Drug Sales Forecast by Type (2026-2031) & (K Pcs)
Table 73. Global Neuroendocrine Tumor Drug Revenue Forecast by Type (2026-2031) & ($ millions)
Table 74. Global Neuroendocrine Tumor Drug Sales Forecast by Application (2026-2031) & (K Pcs)
Table 75. Global Neuroendocrine Tumor Drug Revenue Forecast by Application (2026-2031) & ($ millions)
Table 76. Eisai Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 77. Eisai Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 78. Eisai Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 79. Eisai Main Business
Table 80. Eisai Latest Developments
Table 81. Exelixis, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 82. Exelixis, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 83. Exelixis, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 84. Exelixis, Inc. Main Business
Table 85. Exelixis, Inc. Latest Developments
Table 86. Foresee Pharmaceuticals, LLC Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 87. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 88. Foresee Pharmaceuticals, LLC Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 89. Foresee Pharmaceuticals, LLC Main Business
Table 90. Foresee Pharmaceuticals, LLC Latest Developments
Table 91. Hutchison MediPharma Limited Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 92. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 93. Hutchison MediPharma Limited Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 94. Hutchison MediPharma Limited Main Business
Table 95. Hutchison MediPharma Limited Latest Developments
Table 96. Intezyne, Inc Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 97. Intezyne, Inc Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 98. Intezyne, Inc Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 99. Intezyne, Inc Main Business
Table 100. Intezyne, Inc Latest Developments
Table 101. INVENT Pharmaceuticals, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 102. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 103. INVENT Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 104. INVENT Pharmaceuticals, Inc. Main Business
Table 105. INVENT Pharmaceuticals, Inc. Latest Developments
Table 106. Ipsen S.A. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 107. Ipsen S.A. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 108. Ipsen S.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 109. Ipsen S.A. Main Business
Table 110. Ipsen S.A. Latest Developments
Table 111. Jiangsu Hengrui Medicine Co., Ltd. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 112. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 113. Jiangsu Hengrui Medicine Co., Ltd. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 114. Jiangsu Hengrui Medicine Co., Ltd. Main Business
Table 115. Jiangsu Hengrui Medicine Co., Ltd. Latest Developments
Table 116. Karyopharm Therapeutics, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 117. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 118. Karyopharm Therapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 119. Karyopharm Therapeutics, Inc. Main Business
Table 120. Karyopharm Therapeutics, Inc. Latest Developments
Table 121. Lexicon Pharmaceuticals, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 122. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 123. Lexicon Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 124. Lexicon Pharmaceuticals, Inc. Main Business
Table 125. Lexicon Pharmaceuticals, Inc. Latest Developments
Table 126. Midatech Pharma Plc . Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 127. Midatech Pharma Plc . Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 128. Midatech Pharma Plc . Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 129. Midatech Pharma Plc . Main Business
Table 130. Midatech Pharma Plc . Latest Developments
Table 131. Millennium Pharmaceuticals, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 132. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 133. Millennium Pharmaceuticals, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 134. Millennium Pharmaceuticals, Inc. Main Business
Table 135. Millennium Pharmaceuticals, Inc. Latest Developments
Table 136. MolMed S.p.A. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 137. MolMed S.p.A. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 138. MolMed S.p.A. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 139. MolMed S.p.A. Main Business
Table 140. MolMed S.p.A. Latest Developments
Table 141. Northwest Biotherapeutics, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 142. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 143. Northwest Biotherapeutics, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 144. Northwest Biotherapeutics, Inc. Main Business
Table 145. Northwest Biotherapeutics, Inc. Latest Developments
Table 146. Novartis AG Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 147. Novartis AG Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 148. Novartis AG Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 149. Novartis AG Main Business
Table 150. Novartis AG Latest Developments
Table 151. OctreoPharm Sciences GmbH Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 152. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 153. OctreoPharm Sciences GmbH Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 154. OctreoPharm Sciences GmbH Main Business
Table 155. OctreoPharm Sciences GmbH Latest Developments
Table 156. OXiGENE, Inc. Basic Information, Neuroendocrine Tumor Drug Manufacturing Base, Sales Area and Its Competitors
Table 157. OXiGENE, Inc. Neuroendocrine Tumor Drug Product Portfolios and Specifications
Table 158. OXiGENE, Inc. Neuroendocrine Tumor Drug Sales (K Pcs), Revenue ($ Million), Price (USD/Pcs) and Gross Margin (2020-2025)
Table 159. OXiGENE, Inc. Main Business
Table 160. OXiGENE, Inc. Latest Developments


List of Figures
Figure 1. Picture of Neuroendocrine Tumor Drug
Figure 2. Neuroendocrine Tumor Drug Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Neuroendocrine Tumor Drug Sales Growth Rate 2020-2031 (K Pcs)
Figure 7. Global Neuroendocrine Tumor Drug Revenue Growth Rate 2020-2031 ($ millions)
Figure 8. Neuroendocrine Tumor Drug Sales by Geographic Region (2020, 2024 & 2031) & ($ millions)
Figure 9. Neuroendocrine Tumor Drug Sales Market Share by Country/Region (2024)
Figure 10. Neuroendocrine Tumor Drug Sales Market Share by Country/Region (2020, 2024 & 2031)
Figure 11. Product Picture of mTOR Protein Inhibitors
Figure 12. Product Picture of Tyrosine Kinase 3 Inhibitors
Figure 13. Product Picture of Somatostatin Receptor Antagonists
Figure 14. Product Picture of Growth Hormone Releasing Factor Antagonists
Figure 15. Product Picture of Somatostatin Receptor Agonists
Figure 16. Product Picture of Others
Figure 17. Global Neuroendocrine Tumor Drug Sales Market Share by Type in 2025
Figure 18. Global Neuroendocrine Tumor Drug Revenue Market Share by Type (2020-2025)
Figure 19. Neuroendocrine Tumor Drug Consumed in Hospital
Figure 20. Global Neuroendocrine Tumor Drug Market: Hospital (2020-2025) & (K Pcs)
Figure 21. Neuroendocrine Tumor Drug Consumed in Clinic
Figure 22. Global Neuroendocrine Tumor Drug Market: Clinic (2020-2025) & (K Pcs)
Figure 23. Neuroendocrine Tumor Drug Consumed in Others
Figure 24. Global Neuroendocrine Tumor Drug Market: Others (2020-2025) & (K Pcs)
Figure 25. Global Neuroendocrine Tumor Drug Sale Market Share by Application (2024)
Figure 26. Global Neuroendocrine Tumor Drug Revenue Market Share by Application in 2025
Figure 27. Neuroendocrine Tumor Drug Sales by Company in 2025 (K Pcs)
Figure 28. Global Neuroendocrine Tumor Drug Sales Market Share by Company in 2025
Figure 29. Neuroendocrine Tumor Drug Revenue by Company in 2025 ($ millions)
Figure 30. Global Neuroendocrine Tumor Drug Revenue Market Share by Company in 2025
Figure 31. Global Neuroendocrine Tumor Drug Sales Market Share by Geographic Region (2020-2025)
Figure 32. Global Neuroendocrine Tumor Drug Revenue Market Share by Geographic Region in 2025
Figure 33. Americas Neuroendocrine Tumor Drug Sales 2020-2025 (K Pcs)
Figure 34. Americas Neuroendocrine Tumor Drug Revenue 2020-2025 ($ millions)
Figure 35. APAC Neuroendocrine Tumor Drug Sales 2020-2025 (K Pcs)
Figure 36. APAC Neuroendocrine Tumor Drug Revenue 2020-2025 ($ millions)
Figure 37. Europe Neuroendocrine Tumor Drug Sales 2020-2025 (K Pcs)
Figure 38. Europe Neuroendocrine Tumor Drug Revenue 2020-2025 ($ millions)
Figure 39. Middle East & Africa Neuroendocrine Tumor Drug Sales 2020-2025 (K Pcs)
Figure 40. Middle East & Africa Neuroendocrine Tumor Drug Revenue 2020-2025 ($ millions)
Figure 41. Americas Neuroendocrine Tumor Drug Sales Market Share by Country in 2025
Figure 42. Americas Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2025)
Figure 43. Americas Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Figure 44. Americas Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Figure 45. United States Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 46. Canada Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 47. Mexico Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 48. Brazil Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 49. APAC Neuroendocrine Tumor Drug Sales Market Share by Region in 2025
Figure 50. APAC Neuroendocrine Tumor Drug Revenue Market Share by Region (2020-2025)
Figure 51. APAC Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Figure 52. APAC Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Figure 53. China Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 54. Japan Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 55. South Korea Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 56. Southeast Asia Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 57. India Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 58. Australia Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 59. China Taiwan Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 60. Europe Neuroendocrine Tumor Drug Sales Market Share by Country in 2025
Figure 61. Europe Neuroendocrine Tumor Drug Revenue Market Share by Country (2020-2025)
Figure 62. Europe Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Figure 63. Europe Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Figure 64. Germany Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 65. France Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 66. UK Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 67. Italy Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 68. Russia Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 69. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Country (2020-2025)
Figure 70. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Type (2020-2025)
Figure 71. Middle East & Africa Neuroendocrine Tumor Drug Sales Market Share by Application (2020-2025)
Figure 72. Egypt Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 73. South Africa Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 74. Israel Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 75. Turkey Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 76. GCC Countries Neuroendocrine Tumor Drug Revenue Growth 2020-2025 ($ millions)
Figure 77. Manufacturing Cost Structure Analysis of Neuroendocrine Tumor Drug in 2025
Figure 78. Manufacturing Process Analysis of Neuroendocrine Tumor Drug
Figure 79. Industry Chain Structure of Neuroendocrine Tumor Drug
Figure 80. Channels of Distribution
Figure 81. Global Neuroendocrine Tumor Drug Sales Market Forecast by Region (2026-2031)
Figure 82. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Region (2026-2031)
Figure 83. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Type (2026-2031)
Figure 84. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Type (2026-2031)
Figure 85. Global Neuroendocrine Tumor Drug Sales Market Share Forecast by Application (2026-2031)
Figure 86. Global Neuroendocrine Tumor Drug Revenue Market Share Forecast by Application (2026-2031)